Dow Jones
38.085,80 -375,12 (-0,98%) Nasdaq
15.611,76 -100,99 (-0,64%) Nikkei 225
37.628,48 -831,60 (-2,16%) EUR/USD
1,0732 +0,0031 (+0,29%) Bitcoin EUR
60.496,81 +812,89 (+1,36%) CMC Crypto 200
1.398,50 +15,93 (+1,15%)
Abeona Therapeutics Inc. (ABEO)
Dopo ore:
| Chiusura precedente | 3,1700 |
| Aperto | 3,8119 |
| Denaro | 3,1400 x 100 |
| Lettera | 3,2200 x 100 |
| Min-Max giorno | 3,0500 - 3,2750 |
| Intervallo di 52 settimane | 2,8300 - 9,0100 |
| Volume | |
| Media Volume | 492.553 |
| Capitalizzazione | 87,262M |
| Beta (5 anni mensile) | 1,48 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -2,5300 |
| Prossima data utili | 09 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 20,50 |
GlobeNewswireAbeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
CLEVELAND, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the Company has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of EB-101, its investigational autologous, engineered cell therapy, as a treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). As part of the submission, Abeona requested a Priority Review, which, if granted, would shorten the FDA’s review perio
- GlobeNewswire
Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
CLEVELAND, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Madhav Vasanthavada, Ph.D., M.B.A. to the role of Chief Commercial Officer (CCO) and Head of Business Development (BD), effective immediately. In this capacity, in addition to his current BD responsibilities, Dr. Vasanthavada will oversee all aspects of commercial strategy, planning and operations as Abeona prepares for a potential launch of EB-101, its investigational, geneti
- GlobeNewswire
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
CLEVELAND, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2023: A company presentation at the H.C. Wainwright Annual Global Investment Conference on Wednesday, September 13, 2023 at 10:00 a.m. ET.A fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 2:10 p.m. ET.A fireside chat at the Jefferies Cell & Genetic Medicin
